Managing type 2 diabetes can sometimes feel like carrying a second job. There are medications to remember, glucose readings to watch, meals to plan, and appointments to schedule. For people who use daily basal insulin, injections become another item on that list. Now, a new generation of weekly basal insulin is giving some adults with type 2 diabetes a different way to manage that routine.
In 2026, the U.S. Food and Drug Administration approved two weekly basal insulin options for adults with type 2 diabetes. Awiqli, or insulin icodec-abae, was approved in March. More recently, Onswik, or insulin efsitora alfa-gobe, was approved in September. Both provide background insulin over seven days instead of requiring a basal injection every day.
Table of Contents
- How weekly insulin could change type 2 diabetes care
- How weekly basal insulin works
- Who may be a candidate
- Benefits, risks, and the diabetes mental load
- Conclusion
- Frequently asked questions
How Weekly Insulin Could Change Type 2 Diabetes Care
Basal insulin works in the background. Unlike mealtime insulin, which helps control glucose increases after eating, basal insulin helps keep blood sugar more stable between meals and overnight. The American Diabetes Association describes basal insulin as the background insulin the body needs throughout the day and night.
Traditionally, long-acting basal insulin has usually meant one injection every day. Therefore, someone following that schedule could take about 365 basal injections each year.
A weekly treatment changes that routine in a major way. One injection per week works out to roughly 52 basal injections per year.
That difference could matter to people who struggle with injection fatigue, complicated medication schedules, travel, or simply remembering another daily task. However, fewer injections do not mean diabetes becomes a once-a-week condition. Glucose monitoring, healthy eating, activity, other medications, and regular medical care may still be important.
The HealingWell diabetes community also reflects how much daily decision-making can come with diabetes. Treatment convenience is only one part of that broader experience.
How Does Weekly Basal Insulin Work?
Weekly basal insulin is designed to stay active in the body much longer than traditional daily basal insulin. Instead of delivering one day of background insulin, each dose is designed to provide basal coverage across a seven-day period.
Awiqli was the first FDA-approved weekly basal insulin in the United States for adults with type 2 diabetes. The FDA approved it in March 2026. Onswik became the second option when the agency approved it in September 2026.
Clinical studies compared these medicines with established daily basal insulins. In trials reviewed by the FDA, weekly treatment was able to lower A1C in adults with type 2 diabetes. In several studies, the reductions were comparable with those seen with commonly used daily basal insulins.
Still, a seven-day dosing schedule requires patients and clinicians to think differently about insulin timing and dose management. A single dose remains active for days. Consequently, taking the wrong dose or accidentally taking another weekly dose too soon may have longer-lasting effects than a mistake with a shorter-acting medication.
That is why once-weekly insulin should be used exactly as prescribed. Patients also need clear instructions about what to do if a dose is missed or taken at the wrong time.
Who Could Be a Candidate for Weekly Basal Insulin?
The weekly basal insulins currently approved by the FDA are intended for adults with type 2 diabetes who need insulin to improve blood sugar control. They are not treatments that everyone using insulin should automatically switch to.
For example, Onswik is not recommended for people with type 1 diabetes because of an increased risk of severe hypoglycemia. Awiqli's U.S. approval is also specifically for adults with type 2 diabetes.
Someone already taking daily basal insulin may wonder whether switching could simplify treatment. Meanwhile, another person may be considering insulin for the first time after other medications no longer provide enough glucose control.
In either situation, the decision requires individualized medical guidance. Current insulin doses, kidney or liver function, other diabetes medicines, glucose patterns, and previous episodes of low blood sugar can all affect treatment decisions.
If you are considering a change in diabetes therapy, discussing your medication history with your regular care team or a qualified clinician through a resource such as Healthcare.pro may help you better understand your options.
Could Fewer Injections Reduce the Diabetes Mental Load?
The most obvious advantage of a weekly basal insulin is convenience. Going from a daily basal injection to just one each week could mean hundreds fewer injections over the course of a year.
That may sound like a simple logistical change, but chronic illness management is built from repeated tasks. Every glucose check, refill, injection, meal decision, and appointment requires attention. Removing one repetitive daily task may therefore feel meaningful for some people.
However, weekly treatment has its own responsibilities. Patients must remember the correct injection day and follow dosing instructions carefully. Moreover, people taking other injectable diabetes medicines need to avoid confusing one product or dose with another.
Low blood sugar, or hypoglycemia, remains one of the most important risks of insulin treatment. Symptoms can include shaking, sweating, hunger, dizziness, weakness, confusion, or a fast heartbeat. The American Diabetes Association's hypoglycemia guidance explains why recognizing and treating low blood sugar quickly matters.
Other possible insulin-related effects include injection-site reactions, weight gain, swelling, and allergic reactions. Therefore, simpler dosing should never be mistaken for risk-free treatment.
For many people, the real benefit may not be simpler diabetes care overall, but one less daily task to manage. That could still make a meaningful difference in how treatment fits into everyday life.
Conclusion
Weekly basal insulin represents a significant change in how some adults with type 2 diabetes can receive long-acting insulin. With Awiqli and Onswik now FDA approved, patients have options that can reduce basal injections from daily dosing to one injection each week.
For some people, that could reduce treatment fatigue and make diabetes management feel a little less intrusive. However, weekly insulin still requires careful dosing, glucose awareness, and ongoing medical supervision.
Ultimately, the biggest change may not be that diabetes becomes simple. Instead, one demanding part of the routine may become easier to manage.
Frequently Asked Questions
What is once-weekly insulin?
Weekly basal insulin is a long-acting form of insulin designed to provide background insulin coverage for seven days after a single injection. Current U.S. options are approved for adults with type 2 diabetes.
Which weekly insulin options are FDA approved?
As of 2026, the FDA has approved Awiqli, or insulin icodec-abae, and Onswik, or insulin efsitora alfa-gobe, for adults with type 2 diabetes.
Does weekly insulin replace all insulin injections?
Not necessarily. It replaces basal insulin dosing for appropriate patients. Someone who also requires mealtime insulin may still need injections around meals.
Is weekly insulin safer than daily insulin?
Weekly dosing may be more convenient, but that does not automatically make it safer. Hypoglycemia and medication errors remain important risks, and the most appropriate insulin depends on each person's medical situation.
Can I switch from daily insulin to weekly insulin on my own?
No. Switching insulin formulations requires specific dose calculations and may require closer glucose monitoring. A healthcare professional should supervise any change in insulin therapy.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.